COSCIENS Biopharma Inc. Increase Decrease Through Foreign Exchange Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts
COSCIENS Biopharma Inc. (CSCIF) reported Increase Decrease Through Foreign Exchange Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts of $1.05 million for the 12-month period ending 2023-12-31, per its 20-F/A filed 2024-07-17.
Discontinued › Notes
ifrs-full:IncreaseDecreaseThroughForeignExchangeExposureToCreditRiskOnLoanCommitmentsAndFinancialGuaranteeContracts · last filed 2024-07-17
- COSCIENS Biopharma Inc. increase decrease through foreign exchange exposure to credit risk on loan commitments and financial guarantee contracts for the quarter ending 2020-12-31 was -$50.00K, a 138.17% decline year-over-year.
- COSCIENS Biopharma Inc. increase decrease through foreign exchange exposure to credit risk on loan commitments and financial guarantee contracts for the quarter ending 2020-09-30 was $123.00K, a 25.00% decline year-over-year.
- COSCIENS Biopharma Inc. increase decrease through foreign exchange exposure to credit risk on loan commitments and financial guarantee contracts for the quarter ending 2020-06-30 was -$13.00K, a 104.71% decline year-over-year.
- COSCIENS Biopharma Inc. increase decrease through foreign exchange exposure to credit risk on loan commitments and financial guarantee contracts for the quarter ending 2020-03-31 was $50.00K, a 81.48% decline year-over-year.
| Period end | Increase Decrease Through Foreign Exchange Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts 3 month | Increase Decrease Through Foreign Exchange Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts 6 month | Increase Decrease Through Foreign Exchange Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts 9 month | Increase Decrease Through Foreign Exchange Exposure To Credit Risk On Loan Commitments And Financial Guarantee Contracts 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.05M 20-F/A · filed 2024-07-17 | |||
| 2022-12-31 | $823.00K 20-F/A · filed 2024-07-17 | |||
| 2021-12-31 | $300.00K 20-F/A · filed 2024-07-17 | |||
| 2020-12-31 | -$50.00K derived: 20-F/A 12 month − 6-K 9 month · filed 2024-02-15 | $73.00K derived: sum of 2 quarters · filed 2024-02-15 | $60.00K derived: sum of 3 quarters · filed 2024-02-15 | $110.00K 20-F/A · filed 2024-02-15 |
| 2020-09-30 | $123.00K derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $110.00K derived: sum of 2 quarters · filed 2020-11-05 | $160.00K 6-K · filed 2020-11-05 | $291.00K derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-06-30 | -$13.00K derived: 6-K 6 month − 6-K/A 3 month · filed 2020-08-06 | $37.00K 6-K · filed 2020-08-06 | $168.00K derived: sum of 3 quarters · filed 2022-03-29 | $332.00K derived: sum of 4 quarters · filed 2022-03-29 |
| 2020-03-31 | $50.00K 6-K/A · filed 2020-05-11 | $181.00K derived: sum of 2 quarters · filed 2022-03-29 | $345.00K derived: sum of 3 quarters · filed 2022-03-29 | $621.00K derived: sum of 4 quarters · filed 2022-03-29 |
| 2019-12-31 | $131.00K derived: 20-F 12 month − 6-K 9 month · filed 2022-03-29 | $295.00K derived: sum of 2 quarters · filed 2022-03-29 | $571.00K derived: sum of 3 quarters · filed 2022-03-29 | $841.00K 20-F · filed 2022-03-29 |
| 2019-09-30 | $164.00K derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $440.00K derived: sum of 2 quarters · filed 2020-11-05 | $710.00K 6-K · filed 2020-11-05 | $444.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $276.00K derived: 6-K 6 month − 6-K/A 3 month · filed 2020-08-06 | $546.00K 6-K · filed 2020-08-06 | $280.00K derived: sum of 3 quarters · filed 2020-08-06 | $500.00K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $270.00K 6-K/A · filed 2020-05-11 | $4.00K derived: sum of 2 quarters · filed 2020-05-11 | $224.00K derived: sum of 3 quarters · filed 2020-05-11 | |
| 2018-12-31 | -$266.00K derived: 20-F 12 month − 6-K 9 month · filed 2020-03-31 | -$46.00K derived: sum of 2 quarters · filed 2020-03-31 | $1.13M 20-F · filed 2020-03-31 | |
| 2018-09-30 | $220.00K derived: 6-K 9 month − 6-K 6 month · filed 2019-11-07 | $1.40M 6-K · filed 2019-11-07 | ||
| 2018-06-30 | $1.18M 6-K · filed 2019-08-13 | |||
| 2017-12-31 | $1.09M 20-F · filed 2019-04-01 |